On November 28, 2022, IKENA Oncology (IKENA; Boston, MA, USA), announced that they will discontinue internal clinical development of the EP4 antagonist IK-007(AAT-007) and will explore strategic alternatives. In addition, Ikena announced that they will present the results of the clinical study of IK-007 in combination with pembrolizumab (Keytruda®) in patients with unresectable or advanced microsatellite stable colorectal cancer in a poster at the 2022 European Society for Medical Oncology Immuno-Oncology Congress.
The investigator-initiated clinical trial of IK-007 in metastatic inflammatory breast cancer (led by Naoto Ueno, M.D., of the University of Texas MD Anderson Cancer Center), initiated in September 2021, is ongoing
For more information, please refer to IKENA’s press release.
